


Supplementary Figure 4



Supplementary Figure 4. NSCs respond postnatally to exogenous DLK1 treatment. (a) Secondary spheres formed by isolated $Dlk1^{+/+}$ and $Dlk1^{-/-}$ NSCs, after pre-treatment (previous passage; see schematic) with increasing concentrations of recombinant DLK1. (b) Percentage of activated caspase3 positive cells 24h after DLK1 treatment. No changes in cell survival were observed. DAPI (blue) was used for counterstaining. (c) Fluorescence and phase contrast photographs of NSCs and astrocytes transduced with *Dlk1* isoforms constructs. (d) Schematic drawing representing the two different *Dlk1* isoforms constructs generated: S-*Dlk1*, the secreted form; MB-*Dlk1* the membrane-tethered form. sp: signal peptide; pr: proteolytic cleavage domain; tm: transmembrane domain. (e) Primary spheres formed by SVZs from $Dlk1^{+/+}$ and $Dlk1^{tg/+}$ mice. No change in neurosphere formation was observed. * $p < 0.05$, ** $p < 0.01$. Error bars, s.e.m of three independent experiments with three cultures per genotype. Scale bars: in b, 60 μm ; in c, 20 μm .